Factors associated with first- and second-line attrition among metastatic breast cancer patients

被引：0
|
作者：
Blondeaux, Eva
Boni, Luca
Chila, Giovanna
Dri, Arianna
Caputo, Roberta
Poggio, Francesca
Fabi, Alessandra
Arpino, Grazia
Pravisano, Federico
Geuna, Elena
Ruelle, Tommaso
Giannubilo, Irene
de Laurentiis, Michelino
Puglisi, Fabio
Bighin, Claudia
Lambertini, Matteo
Montemurro, Filippo
Del Mastro, Lucia
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO3-06-01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO3-06-01
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Health-related quality of life in patients with metastatic colorectal cancer treated with panitumumab in first- or second-line treatment
    Bennett, L.
    Zhao, Z.
    Barber, B.
    Zhou, X.
    Peeters, M.
    Zhang, J.
    Xu, F.
    Wiezorek, J.
    Douillard, J-Y
    BRITISH JOURNAL OF CANCER, 2011, 105 (10) : 1495 - 1502
  • [32] Phase II study of eribulin mesylate as first- or second-line therapy for metastatic HER2-negative breast cancer
    Iwamoto, Mitsuhiko
    Sato, Nayuko
    Terasawa, Rise
    Fujioka, Hiroya
    Takahashi, Yuko
    Kimura, Kasai
    Tanaka, Satoru
    Uchiyama, Kazuhisa
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [33] Health-related quality of life in patients with metastatic colorectal cancer treated with panitumumab in first- or second-line treatment
    Bennett, L.
    Zhao, Z.
    Barber, B.
    Zhou, X.
    Peeters, M.
    Zhang, J.
    Xu, F.
    Wiezorek, J. S.
    Douillard, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [34] Health-related quality of life in patients with metastatic colorectal cancer treated with panitumumab in first- or second-line treatment
    L Bennett
    Z Zhao
    B Barber
    X Zhou
    M Peeters
    J Zhang
    F Xu
    J Wiezorek
    J-Y Douillard
    British Journal of Cancer, 2011, 105 : 1495 - 1502
  • [35] Improving Antimicrobial Prescribing: A Multinomial Model Identifying Factors Associated With First- and Second-Line Prescribing
    Tandan, Meera
    Burns, Karen
    Murphy, Helen
    Hennessy, Sarah
    Cormican, Martin
    Vellinga, Akke
    JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION, 2019, 20 (05) : 624 - 628
  • [36] Coronary angiography: first- or second-line examination?
    Danchin, N
    Angioi, M
    Fattah, IA
    Jacquemin, L
    ANNALES DE CARDIOLOGIE ET D ANGEIOLOGIE, 1997, 46 (08): : 493 - 497
  • [37] Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer
    Borner, MM
    Dietrich, D
    Stupp, R
    Moran, R
    Honegger, H
    Wernli, M
    Herrmann, R
    Pestalozzi, BC
    Saletti, P
    Hanselmann, S
    Müller, S
    Brauchli, P
    Castiglione-Gertsch, M
    Goldhirsch, A
    Roth, AD
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (07) : 1759 - 1766
  • [38] Survival Outcomes Associated with First and Second-Line Palliative Systemic Therapies in Patients with Metastatic Bladder Cancer
    Beigi, Arshia
    Vafaei-Nodeh, Saba
    Huang, Longlong
    Sun, Shaun Z.
    Ko, Jenny J.
    CURRENT ONCOLOGY, 2021, 28 (05) : 3812 - 3824
  • [39] First- and second-line therapy for advanced nonsmall cell lung cancer
    Sculier, J-P.
    Moro-Sibilot, D.
    EUROPEAN RESPIRATORY JOURNAL, 2009, 33 (04) : 915 - 930
  • [40] First- and second-line drug resistance patterns among previously treated tuberculosis patients in India
    Paramasivan, C. N.
    Rehman, F.
    Wares, F.
    Mohan, N. Sundar
    Sundar, S.
    Devi, S.
    Narayanan, P. R.
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2010, 14 (02) : 243 - 246
12345